US Patent

US10195375 — Airflow adaptor for a breath-actuated dry powder inhaler

Formulation · Assigned to Norton Healthcare Ltd · Expires 2031-02-14 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an airflow adaptor for a breath-actuated dry powder inhaler that allows air to flow independently of a conduit.

USPTO Abstract

An airflow adaptor for a breath-actuated dry powder inhaler. The airflow adaptor includes a conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, and wherein the airflow adaptor further includes provisions for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor.

Drugs covered by this patent

Patent Metadata

Patent number
US10195375
Jurisdiction
US
Classification
Formulation
Expires
2031-02-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Norton Healthcare Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.